DIMERIX LIMITED

3.92%

49.0¢

Market Cap $294.0M

Healthcare Biotechnology

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Latest Threads

Tag

Subject

DXB

DXB Chart

45 46 47

21:26

2.8K

1.1M

21:26

Last post bricklebar

2.8K

1.1M

DXB Medicine

DXB Media thread.

10 11 12

11:23

706

344K

11:23

Last post firelines

706

344K

DXB

Broker Reports

2 3

08/09/25

150

32K

08/09/25

Last post RYNZN

150

32K

DXB

Ann: Investor Presentation

05/09/25

4.6K

05/09/25

Last post singhgu

4.6K

DXB

Banter and general comments

2 3

01/09/25

174

76K

01/09/25

Last post ma420

174

76K

DXB

Ann: Appendix 4E and 2025 Annual Report

29/08/25

6.5K

29/08/25

Last post kdwc

6.5K

DXB

Ann: Appendix 4G and Corporate Governance Statement

28/08/25

241

28/08/25

Last post

ASX News

241

DXB

Ann: Investor Presentation and Recording

19/08/25

5.2K

19/08/25

Last post asx11

5.2K

See All Discussions

Timeline

Investor Presentation
03 Sep 09:07	Share

Appendix 4G and Corporate Governance Statement
28 Aug 09:29	Share

Appendix 4E and 2025 Annual Report
28 Aug 09:06	Share

Investor Presentation and Recording
19 Aug 08:57	Share

Cleansing Notice
12 Aug 15:08	Share

Application for quotation of securities - DXB
12 Aug 15:02	Share

Dimerix presentation at Bioshares Biotech Summit
07 Aug 09:05	Share

Quarterly Appendix 4C and Activities Report
25 Jul 08:35	Share

Change of Director's Interest Notice - SP
07 Jul 15:46	Share

Application for quotation of securities - DXB
01 Jul 12:23	Share

Dimerix receives 1st Development Milestone payment from FUSO
30 Jun 08:33	Share

Application for quotation of securities - DXB
27 Jun 15:22	Share

Application for quotation of securities - DXB
24 Jun 14:19	Share

Change of Director's Interest Notice - SP
23 Jun 13:27	Share

Application for quotation of securities - DXB
19 Jun 14:47	Share

Investor Presentation
19 Jun 08:21	Share

Application for quotation of securities - DXB
17 Jun 15:22	Share

ACTION3 Clinical Trial Milestone Recruitment Update
13 Jun 08:58	Share

Application for quotation of securities - DXB
12 Jun 12:02	Share

Application for quotation of securities - DXB
10 Jun 11:46	Share

Application for quotation of securities - DXB
05 Jun 15:47	Share

Application for quotation of securities - DXB
03 Jun 11:38	Share

1st ACTION3 site in Japan activated and milestone triggered
30 May 08:26	Share

Application for quotation of securities - DXB
29 May 13:28	Share

Notification of upcoming expiry of Listed Options
29 May 09:25	Share

Application for quotation of securities - DXB
27 May 14:02	Share

Application for quotation of securities - DXB
22 May 11:53	Share

Successful planned IDMC review of ACTION3 trial
22 May 08:31	Share

Change in substantial holding
20 May 13:07	Share

Application for quotation of securities - DXB
20 May 13:06	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 49.0¢		Change -0.020(3.92%)		Mkt cap ! $294.0M

Open	High	Low	Value	Volume
51.0¢	51.0¢	48.0¢	$404.4K	821.5K

Buyers (Bids)

No.	Vol.	Price($)
1	2063	48.5¢

Sellers (Offers)

Price($)	Vol.	No.
49.0¢	19719	2

View Market Depth

No.	Vol.	Price($)
1	2063	0.485
9	105758	0.480
1	6315	0.475
6	422127	0.470
3	108154	0.465

Price($)	Vol.	No.
0.490	19719	2
0.495	29994	3
0.500	43500	3
0.505	20000	1
0.510	72733	3

Last trade - 16.10pm 09/09/2025 (20 minute delay)


Last 49.0¢		Change -0.020 ( 3.14 %)
Open	High	Low	Volume
50.5¢	50.5¢	48.0¢	324665
Last updated 15.59pm 09/09/2025 ?

DXB (ASX) Chart

DIMERIX LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Dimerix (ASX:DXB) to pocket $2.8m in R&D tax incentive prepayment

17 Feb 2023 10:56 (AEDT)

Dimerix (ASX:DXB) receives FDA approval to include teenagers in kidney disease study

12 Jan 2023 09:16 (AEDT)

Latest Articles

Dimerix launches key trial in Japan as recruitment kicks off

Dimerix (ASX:DXB) has kicked off a key trial in Japan (in terms of patient recruitment) seeking to treat inflammatory diseases.

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

Dimerix has received the first multi-million dollar payment from its Japanese partner FUSO and expects those to continue.

Dimerix signs up first patient for 'highly significant' paediatric clinical trial

Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3 clinical trial in a major next step for the research.The trial will investigate the efficacy of DMX-200 in children aged 12 to 17 with focal seg...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News